29 Mar Risks of Anaphylaxis With IV Iron Infusions Assessed
MedicalResearch.com Interview with:
Dr. Dave
Chintan V. Dave, PharmD, PhD
Assistant Professor
Ernest Mario School of Pharmacy
Institute for Health, Health Care Policy and Aging Institute
Rutgers University
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: The risks of anaphylaxis among intravenous (IV) iron products currently in use has not been assessed. Older adults have a higher risk of experiencing drug-induced anaphylaxis. Accordingly, our study objective was to elucidate the risk of anaphylaxis among older adults receiving the five frequently used IV iron products: ferric carboxymaltose, ferumoxytol, ferric gluconate, iron dextran, and iron sucrose.
MedicalResearch.com: What are the main findings? Are there any predictors of increased risk?
Response: Our study revealed that the overall rates of anaphylaxis with all five IV iron products studied were very low, but relatively greater for ferumoxytol and iron dextran (including the low molecular weight version). For older patients at higher risk or medical history of anaphylaxis, ferric carboxymaltose, ferric gluconate, or iron sucrose may be preferable over iron dextran.
MedicalResearch.com: What should readers take away from your report? Are there any predictors of increased risk?
Response: Our investigation offers important insights into the understanding of the differences in risk of anaphylaxis due to IV iron use. By clarifying the risk of this rare, but severe adverse reaction, this information, can be used to contribute to the choice of IV iron preparations. We would like to emphasize that the risk of anaphylaxis is just one of many factors one should consider when deciding on the choice of IV iron therapy. Other factors include clinical indication, setting, dose, the number and duration of administrations required to replenish iron reserves, risk of other adverse reactions, and costs.
We have no conflicts of interest to disclose.
Citation:
Chintan V. Dave, Gary M. Brittenham, Jeffrey L. Carson, et al. Risks for Anaphylaxis With Intravenous Iron Formulations: A Retrospective Cohort Study. Ann Intern Med. [Epub ahead of print 29 March 2022]. doi:10.7326/M21-4009
[wysija_form id=”3″]
[last-modified]
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. Some links may be sponsored and no links are warranted or endorsed by MedicalResearch.com or its parent company, Eminent Domains Inc. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on March 29, 2022 by Marie Benz MD FAAD